Phone: (707) 546-5553
Email Us
1140 Sonoma Avenue 1-A
Santa Rosa, CA 95405

Monthly Archives: November 2015

First Prostate Cancer Patient Treated with Minimally Invasive HIFU on West Coast

Dr. Michael Lazar performing first HIFU surgery on the West Coast at San Francisco Surgery Center

Dr. Michael Lazar performing first HIFU surgery on the West Coast at San Francisco Surgery Center

November 18, 2015. San Francisco, CA – HIFU Prostate Services, LLC, a leading provider of minimally- invasive prostate cancer treatment, using High Intensity Focused Ultrasound (HIFU), announced that physician partner and Medical Director, Michael J. Lazar, MD treated the first prostate cancer patient in California with minimally invasive HIFU on November 18, in San Francisco at the San Francisco Surgery Center (SFSC). This will be the second patient ever treated in the country using Sonablate HIFU technology.

HIFU Prostate Services has partnered with Lazar and SFSC to establish a HIFU Center of Excellence where patients can receive the recently FDA-cleared Sonablate HIFU treatment. SFSC is located in downtown San Francisco, near Union Square, which offers patients a state-of-the-art facility in downtown that is convenient to hotels and the airport for men who will be traveling from around the country for this non-invasive treatment.

Lazar, who also serves as Medical Director of HIFU Prostate Services, has been working with HIFU since 2007, and was one of three physicians who proctored cases during clinical trials. Lazar will offer HIFU treatment to qualified patients and also provide medical guidance and serve as a proctor to physicians that are being trained on the Sonablate® HIFU system in San Francisco and surgery centers around the country.

Kevin Wienke, Administrator of the San Francisco Surgery Center states, “The Center is proud to be able to receive one of the first Sonablate® HIFU Systems in the country and to partner with Dr. Lazar and HIFU Prostate Services to offer our patients a viable option for prostate cancer.”

John W. Linn, chief executive officer of HIFU Prostate Services said, “The Sonablate® is the first device to receive regulatory authorization from the FDA for the ablation of prostate tissue. HIFU has been available in other countries for more than 10 years, but we are proud to be the first to make this game-changing technology available in the United States”.

Since 2004, approximately 4,000 U.S. men have been treated outside the U.S. where this technology is approved in over 30 countries. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence, which are typically reported with surgery and radiation.

Ken Hicks, a patient of Dr. Lazar’s who received HIFU treatment in 2007 in Puerto Vallarta, Mexico says, “Finally men in the U.S. can receive this innovative, minimally invasive therapy for their prostate cancers without traveling internationally. I still can’t believe I was eating dinner on the beach just hours after my HIFU procedure and I am doing great after 7 years. I highly recommend Dr. Lazar and HIFU to anyone who is eligible for this incredible procedure.”

About Dr. Michael Lazar

Lazar HIFU

A great medical partnership begins in San Francisco. Kevin Wienke (L), Administrator SF-SC and Dr. Michael Lazar (R), Director of HIFU Prostate Services.

Dr. Lazar is currently the Medical Director of HIFU Prostate Services (HPS) and clinical partner with HPS and SFSC with the HIFU program. He has been certified by the American Board of Urology four times and has practiced in Santa Rosa, Calif. since 1983. He is chairman of the Board of Redwood Health Services, Inc. providing insurance products for employee groups. Lazar is also CEO and managing director of Santa Rosa Surgical Management Company, LLC that manages the ambulatory surgery center at Santa Rosa Memorial Hospital. Lazar received his urology training at Louisiana State University in New Orleans, La. and is a graduate of University of Arkansas Medical School.

For more information on Dr. Lazar, visit www.californiahifu.com

About HIFU Prostate Services, LLC

HIFU Prostate Services (HPS) was founded in 2015 to provide men access to a less invasive treatment option for prostate disease focused on preserving quality of life. The mission of HPS is to partner with physicians to deliver the highest quality of care, support and technology to the patient and to the urology community for the treatment of localized prostate cancer using high intensity focused ultrasound (HIFU). HPS is lead by a seasoned management team with over 50 years of experience in the healthcare industry and over 30 years focused on HIFU technologies The company is headquartered in Charlotte, NC.

For additional information, visit www.hifuprostateservices.com.

By | November 18th, 2015|Dr. Michael Lazar, HIFU, News|0 Comments

Recently FDA approved HIFU for Prostate Cancer makes news in Kentucky

HIFU is making news all over the United States now that it has achieved FDA approval. In the news video below HIFU Prostate Services physician partner, Dr. John Jurige speaks with Louisville’s news station, WHAS about HIFU for prostate cancer. Dr. Jurige treated the first patients in the US with HIFU outside of a clinical trial on November 10, 2015. View the video below …

HIFU Prostate Services has partnered with Dr. Michael Lazar and San Francisco Surgery Center to establish a HIFU Center of Excellence in downtown San Franciso where patients can now receive the Sonablate HIFU treatment. Dr. Lazar also serves as Medical Director of HIFU Prostate Services, has been working with HIFU since 2007, and was one of three physicians who proctored cases during clinical trials.

Dr. Lazar offers HIFU treatment to qualified patients and also provides medical guidance and serves as a proctor to physicians that are being trained on the Sonablate® HIFU system in San Francisco and surgery centers around the country. To learn more about HIFU and who may qualify for this life saving procedure visit our Do You Qualify section.

By | November 18th, 2015|Uncategorized|0 Comments

Minimally Invasive Prostate Cancer Treatment HIFU Now Available in the U.S.

sonablate500After much anticipation the FDA has finally approved for market in the United States the Sonablate® for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence which are typically reported with surgery and radiation.

HIFU Prostate Services, LLC (HPS) is a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). Newly appointed HPS Medical Director Michael J. Lazar, MD is set to provide medical guidance and proctoring to new physicians who will now be trained on the Sonacare® HIFU system in surgery centers around the country. Dr. Lazar has been treating patients with HIFU since 2007 and is one of only three U.S. physicians who worked with SonaCare Medical, LLC to supervise HIFU treatments during FDA clinical trials.

John W. Linn, chief executive officer of HPS commented, “I have known Dr. Lazar since 2007 and have been impressed with his patient care and dedication to the HIFU technology since his first treatment. He is the ideal medical director for HPS and for teaching this new technology to US physicians.”

Lazar will also operate his own HIFU Program in partnership with HPS, offering prostate treatments in downtown San Francisco near Union Square at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility that is convenient to hotels and the airport for patients interested in traveling from around the country for HIFU treatments. The actual Sonablate device has just been delivered to the Surgery Center in San Francisco, marking the first time ever that a HIFU device will be available at a medical center in the United States.

“It is very exciting to be a part of providing the vehicle for access to this technology for new and experienced HIFU users. Over the years, physicians in various stages of training have shown remarkable enthusiasm for providing HIFU for their prostate cancer patients, but they did not see a clear path for obtaining accessibility to the technology after FDA approval,” said Lazar. “HIFU Prostate Services takes the mystery and tedium out of the process by providing the highest quality of care, support and technology to the patient and to the urology community. Men who choose HIFU can contact HPS and then be referred to a regional HIFU surgeon. This approach facilitates wide availability of this treatment option for American men.”

HIFU offers patients a single, outpatient treatment for prostate cancer that is bloodless and allows men to return to their normal lifestyles within a few days. Although HIFU is designed as a single treatment, it can be repeated if needed. HIFU may also be used to treat patients that have failed radiation therapy and it does not preclude any future treatments including surgery or radiation.

About HIFU Prostate Services, LLC & Dr. Michael Lazar

At HIFU Prostate Services (HPS), our mission is to partner with physicians to deliver the highest quality of care, support and technology to the patient and to the urology community for the treatment of localized prostate cancer using high intensity focused ultrasound (HIFU). HPS was founded in 2015 by a seasoned management team with over 50 years of experience in the healthcare industry and over 30 years focused on HIFU technologies The company is headquartered in Charlotte, N.C.

lazar close up

Dr. Michael Lazar

Dr. Michael Lazar has been certified by the American Board of Urology four times and has practiced in Santa Rosa, California since 1983. He is chairman of the Board of Redwood Health Services, Inc. providing insurance products for employee groups. Lazar is also CEO and managing director of Santa Rosa Surgical Management Company, LLC that manages the ambulatory surgery center at Santa Rosa Memorial Hospital. Lazar received his urology training at Louisiana State University in New Orleans, La. and is a graduate of University of Arkansas Medical School.

For additional information, visit Dr. Michael Lazar at www.californiahifu.com, 707-546-5553 or www.hifuprostateservices.com. Media Contact: John Linn, 704-737-5925
.

HIFU Prostate Services Names Michael J. Lazar, MD Medical Director

Nov. 4, 2015 — HIFU Prostate Services (HPS) has named Dr. Michael Lazar as HPS Medical Director. As HPS Medical Director Dr. Lazar will provide medical guidance and proctoring to new physicians that are being trained on the Sonablate® HIFU system in surgery centers around the country. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence, which are typically reported with surgery and radiation. Lazar has been treating with HIFU since 2007 and is one of three US physicians who worked with SonaCare Medical, LLC to supervise HIFU treatments during FDA clinical trials.

Dr. Lazar will operate his own HIFU Program, in partnership with HPS, offering prostate treatments in downtown San Francisco, near Union Square, at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility in downtown that is convenient to hotels and the airport for patients interested in traveling from around the country for this recently FDA-cleared treatment.

By | November 11th, 2015|Dr. Michael Lazar, HIFU, News|0 Comments

HIFU Now Available In the U.S. Ending a Long Awaited FDA Approval Process

sonablate500After much anticipation the FDA has finally approved for market in the United States the Sonablate® for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence which are typically reported with surgery and radiation.

HIFU Prostate Services, LLC (HPS) is a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). Newly appointed HPS Medical Director Michael J. Lazar, MD is set to provide medical guidance and proctoring to new physicians who will now be trained on the Sonacare® HIFU system in surgery centers around the country. Dr. Lazar has been treating patients with HIFU since 2007 and is one of only three U.S. physicians who worked with SonaCare Medical, LLC to supervise HIFU treatments during FDA clinical trials.

John W. Linn, chief executive officer of HPS commented, “I have known Dr. Lazar since 2007 and have been impressed with his patient care and dedication to the HIFU technology since his first treatment. He is the ideal medical director for HPS and for teaching this new technology to US physicians.”

Dr. Lazar will also operate his own HIFU Program in partnership with HPS, offering prostate treatments in downtown San Francisco near Union Square at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility that is convenient to hotels and the airport for patients interested in traveling from around the country for HIFU treatments. The actual Sonablate device has just been delivered to the Surgery Center in San Francisco, marking the first time ever that a HIFU device will be available at a medical center in the United States.

“It is very exciting to be a part of providing the vehicle for access to this technology for new and experienced HIFU users. Over the years, physicians in various stages of training have shown remarkable enthusiasm for providing HIFU for their prostate cancer patients, but they did not see a clear path for obtaining accessibility to the technology after FDA approval,” said Lazar. “HIFU Prostate Services takes the mystery and tedium out of the process by providing the highest quality of care, support and technology to the patient and to the urology community. Men who choose HIFU can contact HPS and then be referred to a regional HIFU surgeon. This approach facilitates wide availability of this treatment option for American men.”

HIFU offers patients a single, outpatient treatment for prostate cancer that is bloodless and allows men to return to their normal lifestyles within a few days. Although HIFU is designed as a single treatment, it can be repeated if needed. HIFU may also be used to treat patients that have failed radiation therapy and it does not preclude any future treatments including surgery or radiation.

About HIFU Prostate Services, LLC & Dr. Michael Lazar

At HIFU Prostate Services (HPS), our mission is to partner with physicians to deliver the highest quality of care, support and technology to the patient and to the urology community for the treatment of localized prostate cancer using high intensity focused ultrasound (HIFU). HPS was founded in 2015 by a seasoned management team with over 50 years of experience in the healthcare industry and over 30 years focused on HIFU technologies The company is headquartered in Charlotte, N.C.

lazar close upLazar has been certified by the American Board of Urology four times and has practiced in Santa Rosa, California since 1983. He is chairman of the Board of Redwood Health Services, Inc. providing insurance products for employee groups. Lazar is also CEO and managing director of Santa Rosa Surgical Management Company, LLC that manages the ambulatory surgery center at Santa Rosa Memorial Hospital. Lazar received his urology training at Louisiana State University in New Orleans, La. and is a graduate of University of Arkansas Medical School.

For additional information, visit Dr. Michael Lazar at www.californiahifu.com, 707-546-5553 or www.hifuprostateservices.com. Media Contact: John Linn, 704-737-5925

By | November 10th, 2015|Dr. Michael Lazar, HIFU, Prostate Cancer|0 Comments